Patents Assigned to Pfizer Inc.
-
Publication number: 20250257052Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.Type: ApplicationFiled: May 2, 2025Publication date: August 14, 2025Applicant: Pfizer Inc.Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
-
Patent number: 12383611Abstract: In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.Type: GrantFiled: September 24, 2020Date of Patent: August 12, 2025Assignee: Pfizer Inc.Inventors: Annaliesa Sybil Anderson, John Lance Perez, Kathrin Ute Jansen, Paul Liberator, Cuiwen Tan, Thomas Richard Jones, Johannes Frederik Beeslaar, Judith Absalon, Jason Douglas Maguire, Shannon Lea Harris
-
Patent number: 12378230Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.Type: GrantFiled: October 9, 2023Date of Patent: August 5, 2025Assignee: Pfizer Inc.Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
-
Patent number: 12378232Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.Type: GrantFiled: December 7, 2021Date of Patent: August 5, 2025Assignee: Pfizer Inc.Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
-
Patent number: 12371425Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.Type: GrantFiled: September 16, 2022Date of Patent: July 29, 2025Assignees: Pfizer Inc., CTXT PTY LTDInventors: Ylva Elisabet Bergman Bozikis, Michelle Ang Camerino, Pei-Pei Kung, Paul Anthony Stupple, Scott Channing Sutton
-
Patent number: 12372536Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.Type: GrantFiled: July 28, 2022Date of Patent: July 29, 2025Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Robert Arch, Jun Zhang, Michelle Mader, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
-
Patent number: 12371499Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.Type: GrantFiled: May 13, 2022Date of Patent: July 29, 2025Assignees: The Regents of the University of California, Pfizer, Inc.Inventors: Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
-
Patent number: 12371507Abstract: The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.Type: GrantFiled: November 7, 2019Date of Patent: July 29, 2025Assignees: Beth Israel Deaconess Medical Center, Pfizer Inc, Cornell UniversityInventors: Lewis C. Cantley, Stephen P. Soltoff, Brooke M. Emerling, Georgios Poulogiannis, Cindy M. Hodakoski, Hui Liu, Irina Apostolou, Brian Gaither Bates, Kimberly Ann Marquette, Eric M. Bennett, Lidia Mosyak, Lioudmila G. Tchistiakova, Edward Christian Rosfjord, Isaac J. Rondon, Chao Bai Huang
-
Publication number: 20250235504Abstract: The invention provides combinations of materials and methods for disease treatment, such as CD47+ cancer treatment. The combinations include a CD47 blocking agent and a taxane.Type: ApplicationFiled: October 26, 2022Publication date: July 24, 2025Applicant: Pfizer Inc.Inventors: Christina Lindsay KIRKHAM, Gloria Hoi Ying LIN, Emma Cecilia LINDEROTH, Penka Slavcheva SLAVOVA-PETROVA, Robert Adam UGER, Natasja Nielsen VILLER
-
Publication number: 20250235510Abstract: Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.Type: ApplicationFiled: January 23, 2025Publication date: July 24, 2025Applicant: Pfizer Inc.Inventors: Robert Gregory Dullea, Kevin James Filipski, Matthew Forrest Sammons
-
Publication number: 20250235460Abstract: Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.Type: ApplicationFiled: January 23, 2025Publication date: July 24, 2025Applicant: Pfizer Inc.Inventors: Robert Gregory Dullea, Kevin James Filipski, Matthew Forrest Sammons
-
Patent number: 12364749Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.Type: GrantFiled: March 29, 2023Date of Patent: July 22, 2025Assignee: Pfizer Inc.Inventors: Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, Kariann Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna Del Pilar Nunez
-
Publication number: 20250228869Abstract: The invention relates to benzodiazepine pyrazolo carboxamides and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of invention inhibit the activity RSV N-proteins and may be useful in the treatment, prevention, suppression, and amelioration of viral infections such as RSV.Type: ApplicationFiled: January 16, 2025Publication date: July 17, 2025Applicant: Pfizer Inc.Inventors: Jan Antoinette Cusi Romero Adams, Samit Kumar Bhattacharya, Matthew Jeremy Barrett, Alexandre Francois Bedernjak, George Stuart Cockerill, James Arthur Dudley Good, Amit Kalgutkar, Raman Sharma, Joseph Tillotson
-
Publication number: 20250230150Abstract: The present invention is directed to intermediates and an efficient process for preparing nirmatrelvir (compound of Formula I) and intermediates useful in the preparation of nirmatrelvir.Type: ApplicationFiled: June 27, 2023Publication date: July 17, 2025Applicant: Pfizer Inc.Inventors: Christophe Philippe Allais, Nga My Do, Samir Ashok Kulkarni, David William Place, John Anthony Ragan, Emma Leigh Rincon, Rodney Matthew Weekly
-
Patent number: 12358897Abstract: The invention relates to compounds of formula I wherein R1 and R2 are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-COV-2 with the compound.Type: GrantFiled: March 31, 2021Date of Patent: July 15, 2025Assignee: Pfizer Inc.Inventors: Robert Steven Kania, Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Forrest Sammons, Jamison Bryce Tuttle
-
Patent number: 12357681Abstract: This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.Type: GrantFiled: December 17, 2021Date of Patent: July 15, 2025Assignee: Pfizer Inc.Inventors: Ye Che, Laurent Oliver Chorro, Robert George Konrad Donald, Matthew Curtis Griffor, Natalie Clare Silmon de Monerri
-
Patent number: 12343389Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.Type: GrantFiled: July 22, 2022Date of Patent: July 1, 2025Assignee: Pfizer Inc.Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
-
Publication number: 20250206756Abstract: Described herein are novel compounds in an isolated or crystalline form, pharmaceutical compositions and methods for the treatment of and prevention of various disorders, in particular, skin disorders like acne.Type: ApplicationFiled: December 19, 2024Publication date: June 26, 2025Applicant: Pfizer Inc.Inventors: Brian Stephen Gerstenberger, Carley Jeanne Sue Heck, Manjinder Singh Lall, Mihir Dineshkumar Parikh, Usa Reilly, Gwenaella Christine Rescourio
-
Patent number: 12331041Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.Type: GrantFiled: November 20, 2023Date of Patent: June 17, 2025Assignee: Pfizer Inc.Inventors: Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, John M. Curto, David J. Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
-
Publication number: 20250188030Abstract: The invention relates to compounds of Formula (1): and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders, and conditions such as cancers.Type: ApplicationFiled: December 6, 2024Publication date: June 12, 2025Applicant: Pfizer Inc.Inventors: Joyann Susan DONALDSON, Rebecca Anne GALLEGO, Jacqui Elizabeth HOFFMAN, Mehran JALAIE, Matthew Scott JEFFREYS, Robert Arnold KUMPF, Justin Ian MONTGOMERY, Sacha NINKOVIC, Gwenaella Christine RESCOURIO, Jillian Elyse SPANGLER, Shouliang YANG
